What Cibalgina Due Fast Treats: Main Uses and Benefits

The purpose of this medicine, which contains the active ingredient ibuprofen, is used for managing symptoms related to physical discomfort, systemic imbalance, and inflammatory states. This active ingredient is generally used to reduce fever and to relieve minor aches and pain. The Lysinate salt formulation may be relevant when symptoms associated with acute or episodic changes become more disruptive during flare-ups.

---

Pain Relief for Acute and Episodic Discomfort

Cibalgina Due Fast is commonly used across conditions characterized by episodic or fluctuating symptom patterns, providing support that helps ease the overall symptom burden. It is relevant for easing the intensity of mild to moderate discomfort associated with symptoms like headache, dental pain, and the manifestations of primary dysmenorrhea. Applied in contexts where symptoms may appear suddenly, this action may assist with maintaining functional stability.

Management of Systemic Symptoms and Fever

The medicine is generally applied across domains where additional symptomatic support is needed, such as in conditions presenting with systemic or localized discomfort and fever, often linked to the common cold and flu. When symptoms create noticeable physiological strain, the preparation is commonly used to help with symptomatic relief, contributing to easing the overall symptom load and supporting general well-being during symptomatic phases.

---

Quick Fact: Relief for Acute Pain, Fever, and Localized Inflammation

Support for Localized Inflammatory Manifestations

The medicine is used in situations involving symptoms related to inflammatory states, commonly linked to acute musculoskeletal pain or discomfort associated with minor soft tissue injuries. Applied across domains where additional symptomatic support is needed, the anti-inflammatory action plays a role in managing symptoms that become more disruptive during flare-ups, which may assist with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility and Non-Eligibility for Cibalgina Due Fast

The eligibility for Cibalgina Due Fast (Ibuprofen Lysinate) is strictly defined by regulatory documents, focusing on age, physical condition, and disease history. Use is primarily established for adults and adolescents over 12 years of age.

Contraindications (Must Not Use)

Official labeling absolutely prohibits the medicine in several patient groups, including:

• Pediatric patients under 12 years of age.
• Individuals with known hypersensitivity to Ibuprofen or other NSAIDs (e.g., aspirin-sensitive asthma).
• Patients with severe renal, hepatic, or cardiac insufficiency (heart failure).
• Patients with active or recurrent gastrointestinal bleeding or peptic ulcers, or a history of NSAID-related perforation.
• Women in the third trimester of pregnancy.
• Patients with active hemorrhages or severe dehydration.

Restricted and Conditional Use

Specific populations may use the medicine only under strict conditions:

• Pregnancy (First and Second Trimesters): Use is restricted and only permitted if clearly necessary, utilizing the lowest effective dose for the shortest duration.
• Elderly Patients: Caution is required, with treatment starting at the lowest possible dose due to an increased risk of adverse reactions.
• Fertility: The medicine is not recommended for women who are actively attempting to conceive.

Officially Documented Drug Interactions

Cibalgina Due Fast, containing Ibuprofen, has formally documented interaction patterns established by regulatory agencies. These restrictions govern co-administration based on pharmacokinetic and pharmacodynamic outcomes, and not general safety advice.

Formal Restrictions and Contraindications

Co-administration is strictly restricted or contraindicated with other NSAIDs, including selective COX-2 inhibitors. Use is formally prohibited with high-dose Methotrexate (over 20 mg per week) and is restricted around the time of coronary artery bypass graft (CABG) surgery. Concomitant use with Alcohol is documented to increase the risk of gastrointestinal bleeding.

Interactions Affecting Risk and Exposure

Interacting Substance/Class	Documented Interaction Outcome
Anticoagulants, Antiplatelets, SSRIs, Corticosteroids	Increased risk of gastrointestinal bleeding or hemorrhage.
Lithium, Methotrexate (low-dose)	Reduced renal clearance, increasing the other medicine's plasma concentration.
CYP2C9 Inhibitors (e.g., Fluconazole)	Increased Ibuprofen plasma concentration.
Diuretics, ACE Inhibitors, ARBs	Reduction in the blood pressure-lowering (antihypertensive) effect.

Mandatory Timing Rules

To prevent interference with the antiplatelet effect of low-dose Aspirin, regulatory documents specify a required timing separation: immediate-release Ibuprofen must be taken at least 8 hours before or at least 30 minutes after the dose of immediate-release low-dose Aspirin. Interaction risks are also noted to be more pronounced in elderly patients and those with pre-existing renal or hepatic impairment.

The physiological actions of Cibalgina Due Fast are rooted in its single active ingredient, Ibuprofen, delivered as the highly soluble Lysinate salt. The drug operates by a core mechanism that modulates key biological pathways involved in nociception and thermal regulation.

Enzyme Inhibition and Mediator Blockade

This medicine acts as a non-selective, reversible competitive inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzyme system. This interaction prevents the COX enzymes from metabolizing Arachidonic Acid into signaling molecules, primarily prostaglandins ( PGE2). This central blockade modifies the early molecular steps that shape both the inflammatory and thermal responses, resulting in a decreased synthesis of these local chemical mediators.

Modulation of Nociceptive and Central Thermoregulatory Pathways

The resulting reduction in PGE2 concentration exerts effects both peripherally and centrally. Peripherally, it dampens the sensitization of nociceptors in affected tissues, resulting in an attenuation of afferent nociceptive signaling. Centrally, the drug reduces PGE2 synthesis in the brain's hypothalamus, which modulates the elevated thermoregulatory set point. The accelerated dissolution profile of the Lysinate salt enhances delivery speed, supporting a rapid kinetic onset of these enzyme-mediated effects.

How to Use Cibalgina Due Fast

The administration of Cibalgina Due Fast, which contains the active substance ibuprofen, follows established guidelines. These instructions define the correct route, standardized dosage, frequency, and time limitations for use.

---

Administration Route and Preparation

The route of administration is oral. The medicine is provided as film-coated tablets, which must be swallowed whole with a glass of water, and should not be chewed or crushed. For patients with a sensitive stomach, the dose may be taken with food or immediately after a meal, although this may result in a delayed onset of action.

Standardized Dosing and Schedule

The standardized dosing regimen establishes an initial dose of 200 mg to 400 mg of ibuprofen equivalent. Subsequent doses of 200 mg or 400 mg may be repeated as needed. To prevent exceeding the authorized limits, the minimum time interval between doses must be at least four hours when administering 200 mg or at least six hours when administering 400 mg. The total daily intake must not exceed 1200 mg in any 24-hour period.

Duration and Special Populations

Cibalgina Due Fast is indicated for short-term use only for the acute management of symptoms. The principle is to use the lowest effective dose for the shortest duration required to achieve symptomatic relief. Administration is generally limited to no more than three days for fever or four to five days for pain without consulting a healthcare professional. Dosing for adolescents (12 years and above) follows the adult maximum daily dose of 1200 mg.

Research evidence / Overview of studies for Cibalgina Due Fast

Evidence for Use in Acute Mild-to-Moderate Pain

The research base includes randomized controlled trials (RCTs) and systematic reviews that explored outcomes related to physical discomfort. These studies primarily targeted conditions characterized by acute or episodic manifestations, such as pain following dental procedures. The trials included adult participants and examined patient-reported outcomes describing perceived discomfort.

Studies examined whether the active ingredient data show patterns related to change in pain measurements when studied against a placebo. Research explored outcomes related to physical discomfort and the time taken to observe changes in symptom intensity. The primary follow-up durations for these pivotal studies were limited to single-dose observation periods, often lasting only 6 to 8 hours. This short-term focus means there is limited information for long-term outcomes.

---

Evidence for General Relief of Fever and Inflammation

The evidence supporting the evaluation of fever and inflammatory states is derived from the established research corpus of its core active substance, Ibuprofen. Studies of this kind have been conducted across broad populations. Research describes patterns related to changes measured in body temperature and outcomes linked to inflammatory or irritative states.

These findings contribute to the understanding of symptom patterns relevant to conditions such as discomfort associated with the common cold or flu. The evidence supporting these general uses is categorized as high-level, reflecting the large volume of research conducted on the Ibuprofen class.

---

Assessment of the Rapid-Absorption Characteristic

The Lysinate salt formulation was evaluated in pharmacokinetic (PK) studies which specifically measured how quickly the active substance is absorbed into the bloodstream. Findings describe patterns observed in these studies where the Lysinate formulation was observed to reach maximum concentration in less time than standard Ibuprofen acid under specific conditions.

However, clinical trials that directly studied the medicine against standard Ibuprofen acid for the outcome of time to onset of change in pain scores have reported variable results. The research describes patterns where the measured time to change in pain scores in the clinical setting was observed to be similar between the two formulations, despite the faster absorption shown in the laboratory. Furthermore, studies exploring the rapid absorption profile noted that this characteristic was observed to be affected by the presence of food.

How to Store and Dispose of Cibalgina Due Fast

The storage and disposal instructions for Cibalgina Due Fast (Ibuprofen Lysinate) are strictly defined by regulatory requirements to ensure product quality and public safety.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C or 30 C and do not use after the expiry date.
Protection	Must be kept out of the sight and reach of children and protected from moisture.
Packaging	Keep the tablets in the original container or packaging until use.

Disposal Instructions

Unused or expired medicine must be discarded according to official pharmaceutical waste guidelines. The preferred method is using a formal drug take-back program. If this is not available, the product should be mixed with an undesirable substance and placed in a sealed container before disposal in the household trash. It is explicitly required that the medicine must not be disposed of via wastewater.